Theravance Biopharma (TBPH) Proxy filing summary

Executive summary

• A definitive proxy statement was filed regarding a proposed transaction with Zymeworks Inc., urging shareholders to review all related materials for important information.

• The company presented results from the Phase 3 CYPRESS Study of ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA), including post hoc analyses and regulatory updates.

• Forward-looking statements highlight risks and uncertainties, including shareholder approval, regulatory outcomes, and potential litigation related to the proposed transaction.

Voting matters and shareholder proposals

• Shareholders are being solicited to vote on the proposed transaction with Zymeworks Inc., with details provided in the definitive proxy statement.

• The interests of directors, executive officers, and certain employees in the transaction may differ from those of shareholders generally.

Executive compensation and say-on-pay

• Information regarding the direct and indirect interests of directors and executive officers in the proposed transaction is available in the proxy statement.